How to access Cuvitru for primary immunodeficiency from Saudi Arabia: 2026 pathway via KFSHRC and KAMC allergy-immunology | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Saudi Arabia diagnoses and manages primary immunodeficiency (PI) patients through allergy-immunology services at KFSHRC Riyadh, KAMC Riyadh and Jeddah, and KFMC. The longstanding domestic IVIG programme is mature. The 2026 question for selected adults and paediatric patients aged 2 and older is whether to convert from monthly IVIG cycle to weekly self-administered subcutaneous Cuvitru and how to source it under SFDA.
Why Cuvitru, why now
Cuvitru (immune globulin subcutaneous, human - klhw) is a 20 percent subcutaneous immune globulin (SCIG) preparation manufactured by Takeda. The US FDA approved Cuvitru in September 2016 for the treatment of primary humoral immunodeficiency (PI) in adults and paediatric patients aged 2 years and older. Conditions covered include congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency. The 20 percent concentration enables smaller weekly subcutaneous infusion volumes than 10 percent products, supporting home self-administration.
The 2026 question for a Saudi Arabia PI patient already on IVIG (Gammagard, Octagam, Privigen, or similar monthly products) is whether to convert to Cuvitru for steadier IgG troughs, reduced wear-off symptoms, less dependence on infusion-chair scheduling, or to address poor venous access. Saudi Arabia has the region's deepest in-country PI service: KFSHRC Riyadh and Jeddah, KAMC Riyadh and Jeddah, King Fahd Medical City (KFMC) Riyadh, and a maturing tertiary network across the major cities. Reserve Meds does not promote one IgG product over another. Alternatives include Hyqvia (hyaluronidase-facilitated SC), Hizentra, Octagam, Gammagard, Privigen, and others.
What Cuvitru is, in plain language
Cuvitru is a clear-to-slightly-opalescent 20 percent immune globulin solution prepared from screened US plasma donors with multiple viral inactivation and removal steps. It is injected under the skin at the abdomen or thigh using a small subcutaneous needle and a portable infusion pump. After clinic-supervised training (typically two to three sessions), the patient or caregiver self-administers at home, usually once weekly. Each infusion takes 60 to 90 minutes depending on dose and number of sites. Steady-state IgG levels are reached after several cycles, typically by week 8 to 12, with flatter and higher troughs than the IVIG sawtooth pattern.
Access pathway in Saudi Arabia
The Saudi Food and Drug Authority (SFDA), established by Royal Decree in 2003, regulates medicine registration, import licensing, and pharmacovigilance under the Drug and Pharmaceutical Establishments Law. Cuvitru is not currently SFDA-registered. Access therefore runs through the SFDA named-patient personal-import pathway or via institutional special-access at KFSHRC, KAMC, or KFMC pharmacy, filed by the treating allergist-immunologist. Saudi Arabia operates the most mature in-country PI service in the GCC; many regional referrals from neighbouring countries flow into KFSHRC for both diagnosis and ongoing management.
The treating physician submits a named-patient import application detailing the PI diagnosis, the rationale for SCIG conversion, prior IVIG experience, and the requested dose and shipment quantity. SFDA reviews and issues an import authorisation per shipment. Reserve Meds sources Cuvitru from a US DSCSA-compliant specialty wholesaler, prepares the manufacturer pedigree and chain-of-custody documentation, and ships under validated cold chain to King Khalid International Airport Riyadh, King Abdulaziz International Airport Jeddah, or King Fahd International Airport Dammam.
Eligibility at a Saudi allergy-immunology clinic
Cuvitru eligibility requires a confirmed PI diagnosis with documented IgG deficiency (often subclass deficiency), impaired specific antibody response (vaccine challenge with pneumococcal polysaccharide or tetanus antigens), or genetic confirmation of a defined PI syndrome. The treating immunologist documents baseline IgG, IgA, IgM, specific antibody responses, infection history (sinopulmonary infections, otitis media, severe or recurrent infections), and confirms self-administration capability. An IgG trough goal is set, typically 5 to 7 g/L or higher when the patient has a documented history of pneumonia or bronchiectasis. KFSHRC paediatric and adult immunology, KAMC immunology, and KFMC services each handle confirmation and management.
Documentation required
The patient and physician should be prepared to provide: a current Saudi national ID (Iqama for residents) or passport; the diagnostic immunology workup including immunoglobulin panels, vaccine-challenge responses, and any genetic testing; documentation of infection history; prior IVIG infusion records and tolerability issues; the treating immunologist's prescription on hospital letterhead; a clinical justification letter detailing the SCIG rationale; the SFDA named-patient import application; and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US export documentation, manufacturer pedigree, and customs packet.
Costs and funding considerations
The annual cost band for Cuvitru in Saudi Arabia is USD 75,000 to 110,000 per patient (SAR 280,000 to 415,000), weight-and-dose dependent. Typical maintenance dosing is 100 to 200 mg/kg per week. The Ministry of Health and the Council of Health Insurance (CHI) rare-disease provision may cover for confirmed PI cases on a case-by-case basis. Private insurance carriers active in Saudi Arabia (Bupa Arabia, Tawuniya, Medgulf, AXA Cooperative, Saudi Re, Walaa) typically cover IVIG and SCIG with pre-authorisation under the chronic-disease formulary when PI is confirmed. Reserve Meds will help structure the insurer or MoH submission with the treating physician.
Typical timeline
Weeks 0 to 2: clinical eligibility review, SFDA filing, prescription preparation, training arrangement. Weeks 2 to 4: shipment arrival at the destination airport, clinic-supervised SC training (two to three sessions), home-environment setup. Weeks 4 to 16: weekly SC infusions at home with patient logs; IgG trough check at week 12. Months 6 and 12: full reassessment, infection-event log review, IgG and infection-frequency comparison versus the prior IVIG era, dose adjustment as needed.
When Cuvitru is the wrong drug
Patients with good venous access and no appetite for self-injection are usually better served by continuing IVIG. Patients unable to reliably self-administer (cognitive impairment, no caregiver support) are safer on IVIG with hospital-supervised infusion. Patients who cannot maintain a weekly schedule may prefer Hyqvia (monthly SC with hyaluronidase). IgA-deficient patients with anti-IgA antibodies require additional caution and discussion of low-IgA product selection with the treating immunologist. Reserve Meds does not promote one IgG product over another.
Frequently asked questions
- Is the pathway legal in Saudi Arabia? Yes. It operates under SFDA named-patient personal-import authorisation or institutional special-access under the Drug and Pharmaceutical Establishments Law.
- Will MoH or my insurance cover Cuvitru? Saudi nationals may secure MoH or CHI rare-disease support case-by-case; private insurance pre-authorisation is generally available where PI is confirmed.
- How is Cuvitru shipped? Validated cold chain (2 to 8 degrees Celsius) with temperature-monitored containers from a US DSCSA-compliant specialty wholesaler to Riyadh, Jeddah, or Dammam airports.
- Can my child use Cuvitru? Cuvitru is FDA-approved for paediatric patients aged 2 and older; paediatric cases in Saudi Arabia are typically managed at KFSHRC paediatric immunology.
- What if Cuvitru is in short supply at the US level? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
Closing
Reserve Meds runs the Cuvitru supply file from the KFSHRC, KAMC, or KFMC allergy-immunology referral through SFDA named-patient authorisation and delivered cold-chain supply. Clinical decisions remain with your treating allergist-immunologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating allergist-immunologist. Reserve Meds does not promote one IgG product over another.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.